ArticleNews reportPHN-06282026-11-03 01:38 CT

PharmaTher targets new U.S. peptide pathway with 3D printed colon-release tablets

Source · 3D Printing Industry

TLDR

PharmaTher says it is developing 3D-printed, colon-release tablets of KPV and BPC-157 for a reported U.S. compounding pathway covering six peptides. The article links the plans to an HHS policy scheduled for publication on October 30, 2026; evidence for the delivery technology remains laboratory-based.

01—Key points

01The company’s initial target is left-sided ulcerative colitis, using Craft Health’s CORR3CT colon-targeting technology.
02A 2023 laboratory study reported up to 75% delivery to a simulated colon using budesonide, not either peptide.
03The article states that neither KPV nor BPC-157 is FDA-approved; supporting peptide research is early and limited.

Why it matters Editorial

The project connects peptide compounding with targeted oral delivery, but the cited evidence does not establish clinical effectiveness for PharmaTher’s planned tablets.

Read the original at 3D Printing Industry↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.